Evotec SE reported €788M of revenue over the trailing twelve months, −1.1% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €788M (to FY2025). Net income: −€104M, trailing twelve months to FY2025. Free cash flow: −€82M, trailing twelve months to FY2025. Operating margin: −7.1%, trailing twelve months to FY2025.

EVOEvotec SE

Healthcare

$1.52-62% 1Y

$1.52

$1.3452 weeks$4.15

EVO as reported

Evotec SE reported €788M of revenue over the trailing twelve months, −1.1% on the year before. 10 reported series are charted on this page, each one as filed.

€788M

Revenue, trailing twelve months · to FY2025 · −1.1% against the twelve months before

Net income: −€104M
Net income · −47% year on year · trailing twelve months to FY2025
Free cash flow: −€82M
Free cash flow · −18% year on year · trailing twelve months to FY2025
Operating margin: −7.1%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for EVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€788M	−1.1%	FY2025
Net income	−€104M	−47%	FY2025
EPS	−€0.58	−48%	FY2025
Gross margin	14%	n/a	FY2025
Operating margin	−7.1%	n/a	FY2025
Net margin	−13%	n/a	FY2025
ROE	−13%	n/a	FY2025
ROA	−6.0%	n/a	FY2025
ROIC	−6.1%	n/a	FY2025
Free cash flow	−€82M	−18%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.